Also immune response corp. I own 60k shares of this company which I bought at .03 and .10. They have 2 trials running, one for MS and one for early HIV.
The 17th Annual Wall Street Analyst Forum to Be Held February 27th-March 2nd, 2006 Wall Street Analyst Forum 2006 NEW YORK--(BUSINESS WIRE)--Jan. 30, 2006--The Wall Street Analyst Forum is hosting its 17th Annual Analyst Forum on February 27th-March 2nd at The Princeton Club on 15 West 43rd St. (between 5th & 6th Ave.) in NYC. Investors are invited to meet with the CEOs/CFOs of NYSE/NASDAQ/AMEX corporations conducting group meetings, breakout sessions & one-on-one meetings. Investors wishing to attend may register via www.analyst-conference.com. Please see the schedule of presenting companies below.
I don't know much about the R&D day. I think, and this is just a guess, that Dr. Saltz will be there to discuss what he knows. After which he will start a CRC study and will no longer be allowed to be associated with YMI as it would be a conflict of interest.
My guess is the CRC study will be in refractory CRC. Imclone/BMY and AMGN/ABGX have run similiar studies so this will be as close as we will get without actually having the drugs go head to head in a trial.
If theracim would have success in this CRC trial similiar to the erby and pani trials the impact would be something special.